Pediatric clerkship

. 5406200019

7 30 2560 10 2560

11
CASP

Randomized controlled trail

CASP 3

o Section A :
o Section B :
o Section C :

Section A :
1)

PICO :

Population (), Intervention (), Comparator

() outcome ()


12

persistent asthma intervention Fluticasone with

salmeterol Fluticasone alone

Safety : First serious asthma-related event

Efficacy : first severe asthma exacerbation, the use of

rescue albuterol or salbutamol

2)

(randomized a parallel design)

2

1:1

Fluticasone with salmeterol 5834

Fluticasone alone 5845

3) ,
RCT double

blind
,
4)

, ,
, p-value
0.05

5) intervention

intervention rescue

therapy albuterol salbutamol

6)
 intention

to treat

loss follow up

loss follow up

Section B :

7)
efficacy
 severe asthma exacerbation

well

controlled ICS+LABA

12-64 safety
 11679 67 74 serious asthma-

related events 34 fluticasonesalmeterol

36 events fluticasone-only 38

33 events hazard ratio was 1.03 (95%CI, 0.64 to

1.66)

8)
primary outcome non-parametric

Wilcoxon test
X test
2

secondary outcome p

value < 0.05

Section C :

9) .

multicenter


10)

severe asthma exacerbation

fluticasonesalmeterol

fluticasone-only serious

asthma-related events
11) ,

fluticasonesalmeterol severe asthma

exacerbation fluticasone-only

serious asthma-related events

Seretide evohaler

25/125 (120 dose) = 642 1 puff BID

10.7 Flixotide evohaler 125 mcg (120

dose) = 535 / 1 puff BID

8.9